Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW HAVEN, Conn., March 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage pharmaceutical company developing and commercializing novel antibiotics to treat...
-
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
-
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE...
-
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
-
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
-
NEW HAVEN, Conn., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
-
— Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion —— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™(meropenem and...
-
NEW HAVEN, Conn., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
-
NEW HAVEN, Conn., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing, and commercializing novel antibiotics to treat...
-
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® - - Peak sales potential of the...